CAMBRIDGE, England--(BUSINESS WIRE)--Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its Amperia™ assay portfolio with the ...

insights from industryDr. Ruizhi WangFounder and CEOAbselion In this interview, News Medical-Life Sciences speaks with Dr. Ruizhi Wang, Founder and CEO of Abselion, about simplifying the ...

Abselion Launches His-tagged Protein Quantification Kit and Sensors for Amperia at PEGS Europe 2025 Ready-to-use solution, developed in collaboration with GenScript, offers rapid and reliable ...

The company highlights how its technology powers large-scale proteomic perturbation studies, unveiling Perturb-PBMC, a 1.4 million–protein PBMC dataset available in the Nomic Portal Nomic Bio (“Nomic” ...

A proteomics data pipeline transforms raw mass spectrometry spectra into biologically interpretable protein-level ...

Protein detection sensitivity has historically lagged behind nucleic acid detection by 2-3 orders of magnitude due to the lack of intrinsic signal amplification. While digital methods such as Single ...

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its Amperia ™ assay portfolio with the launch of its Tagged Protein ...

When confirming antibody concentrations, sizing up proteins, or seeking the perfect formulation for a next-gen biologic, traditional approaches leave researchers tied to the lab bench for way too long ...

The last two weeks have been packed with collaborations for unveiling innovative products and kick-starting prosperous partnerships. From quantifying His-tagged proteins and characterizing mutations ...

The field of targeted protein degradation (TPD) is advancing at an unprecedented pace, offering novel therapeutic strategies for addressing previously undruggable targets. However, efficient and ...